B. Riley notes TG Therapeutics (TGTX) reported Q3 results, pointing to strong 15% sequential quarter-over-quarter growth in Briumvi U.S. sales, resulting in a Q3 beat. On the conference call, the company noted to be going away from its prior practice of reporting on TRx/NRx, which the firm thinks is contributing to intra-day equity weakness given these launch metrics have until recently been a high-confidence proxy for revenue. Management clarified for these to have lost predictive quality as hospitals now make up majority of revenue and remain the fastest growing segment, but this customer segment-related capture rate to TG hub is challenging. B. Riley says it remains a buyer on weakness today, and reiterates a Buy rating on the shares with a price target of $38.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics price target raised to $55 from $49 at H.C. Wainwright
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- TG Therapeutics reports Q3 EPS 2c, consensus 3c
- TG Therapeutics sees FY24 BRIUMVI U.S. revenue target $300M-$305M
- TGTX Earnings this Week: How Will it Perform?